Kensington Investment Counsel LLC Sells 7,293 Shares of TransMedics Group, Inc. $TMDX

Kensington Investment Counsel LLC reduced its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 46.8% in the first quarter, HoldingsChannel.com reports. The fund owned 8,291 shares of the company’s stock after selling 7,293 shares during the quarter. Kensington Investment Counsel LLC’s holdings in TransMedics Group were worth $824,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Harvest Fund Management Co. Ltd bought a new position in TransMedics Group in the third quarter valued at $29,000. North Star Investment Management Corp. bought a new stake in TransMedics Group during the first quarter worth about $30,000. Ascentis Independent Advisors purchased a new position in shares of TransMedics Group in the 1st quarter worth about $30,000. Allworth Financial LP boosted its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Finally, Parallel Advisors LLC increased its position in shares of TransMedics Group by 42.1% during the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $34,000 after purchasing an additional 83 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Performance

NASDAQ:TMDX opened at $78.00 on Thursday. The firm has a market cap of $2.70 billion, a PE ratio of 17.73 and a beta of 1.89. TransMedics Group, Inc. has a fifty-two week low of $60.10 and a fifty-two week high of $156.00. The company has a debt-to-equity ratio of 1.70, a quick ratio of 6.19 and a current ratio of 6.74. The business has a 50 day moving average price of $72.26 and a 200-day moving average price of $101.42.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million during the quarter, compared to the consensus estimate of $174.44 million. During the same quarter in the prior year, the business posted $0.70 EPS. The firm’s revenue for the quarter was up 21.2% on a year-over-year basis. Equities research analysts predict that TransMedics Group, Inc. will post 1.88 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on TMDX shares. Needham & Company LLC decreased their price objective on TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research report on Monday, July 6th. Oppenheimer lowered shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 6th. Stifel Nicolaus upped their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the company a “hold” rating in a research report on Thursday, June 18th. Finally, TD Cowen reaffirmed a “buy” rating and set a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Six research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $129.55.

Insiders Place Their Bets

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director owned 16,642 shares of the company’s stock, valued at $1,249,148.52. This trade represents a 36.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.